Our Team – DynaCord

Keyon Janani

CHIEF EXECUTIVE OFFICER

Keyon performed his graduate studies at the University of Colorado Boulder in the field of Electrical Engineering specializing in Biomedical Applications of Silicon Photonics. He has spent the majority of his life surrounded by the medical industry. He co-founded and helped develop DMS, a leading telemedicine platform followed by becoming the president of Neuro Technology Institute, the largest intraoperative monitoring company in Louisiana. He then went on to found 5 Leaf Laboratories, one of the top hemp product manufacturers and distributors in the gulf coast. In recent years Keyon partnered with Peter Scherp to found DynaCord and enter the pharmaceutical industry.

Peter Scherp, Ph.D.

Chief Scientific Officer

Peter Scherp received his doctorate degree (Dr. rer. nat.) in Biology/Chemistry from the University of Kassel (Germany). He worked as a postdoc at the University of Louisiana at Lafayette on Karl Hasenstein’s NASA-funded project to study root growth in plants. He participated in Dr. Hasenstein’s MFA-Biotube experiment that flew on Space Shuttle Columbia on Mission STS-107. During his second postdoc at Pennington Biomedical Research Center, Peter performed research with the Botanical Research Center to study effects of botanical extracts on insulin resistance in humans. He conducted proteomics analyses of skeletal muscle and adipose-derived stem cells. Peter joined Keyon Janani to found DynaCord with the goal to bring clinical exosome products to the market.

Lucio Miele, M.D., Ph.D.

Independent Regulatory Consultant

Dr. Miele completed his medical training in Italy and his graduate training at the Max-Planck Institute for Molecular Genetics in Berlin. He then completed a fellowship in Human Genetics at the NIH (NICHD). There, he developed: 1) pharmacologically active peptides from human uteroglobin/CC10; 2) novel expression vectors to produce native, clinical-grade disulfide-bonded human proteins and 3) an early version of PCR-ELISA to quantify normal and mutant DNA in patient blood. In 1994, he moved to FDA/CBER as a senior investigator in the Division of Monoclonal Antibodies and member of the Division of Clinical Trials Design and Analysis. He was eventually promoted Acting Chief, Laboratory of Cell Biology. He is the current department head of the LSU School of Medicine, Department of Genetics. Dr. Miele has authored 195 publications in biomedical journals to date. He has served or presently serves on numerous grant review panels for NIH, NCI, NCATS, the DOD and foreign research funding agencies from Canada, the UK, Spain, Italy, the Netherlands and Singapore. He serves as Editor or Associate Editor of a number of biomedical journals, and has served as an advisor to several pharmaceutical and biotechnology companies.